Lawmaker Calls for Probe of Chinese Ingredients in Weight Loss Drugs

A senior member of the upper chamber is reportedly demanding that the nation’s food and drug regulatory agency investigate whether illegal Chinese ingredients are allegedly making their way into weight loss medications within the country’s borders.

The lawmaker from a southern region has called on the regulatory commissioner to probe how far unregulated and illegal Chinese active pharmaceutical ingredients have reportedly penetrated the domestic supply chain — and whether they have ended up in popular weight loss drugs, according to sources familiar with the matter.

“China’s access to [the nation’s] pharmaceutical supply chain presents national security risks as well as significant health risks to [local] patients,” the legislator reportedly wrote in a letter to the commissioner, according to government documents.

The lawmaker’s concerns follow recent reports from regulatory authorities and border protection agencies that between September 2023 and January 2025, officials intercepted 195 illegal shipments of active pharmaceutical ingredients, observers note.

The legislator noted that the ingredients were “likely used in compounded weight loss medications” that entered the domestic market. Of those shipments, roughly 60 reportedly originated from China and Hong Kong.

“It is estimated that as of January 2026, up to 1.5 million [local] patients could be using unregulated compounded weight loss medications that may contain potentially dangerous ingredients from Chinese manufacturers,” the lawmaker allegedly wrote.

The ingredients are typically used in compounded versions of GLP-1 weight loss drugs that are marketed as alternatives to officially approved medications, according to industry analysts.

Earlier this month, the nation’s health department announced it would refer a telehealth company to the Justice Department for “potential violations” over its planned sale of a compounded, non-approved weight loss drug, sources reported.

The regulatory commissioner similarly said the agency would “take decisive steps to restrict GLP-1 active pharmaceutical ingredients intended for use in non-approved compounded drugs that are being mass-marketed by companies,” according to official statements.

The company announced last week that it would remove its weight loss pill, billed as a cheaper alternative to approved medications, from the market following mounting pressure from federal agencies, observers note.

The legislator acknowledged that move and called for similar investigations going forward, reportedly stating: “I encourage further investigations into other entities that expose [local] patients to dangerous, unregulated Chinese APIs.”

This development reflects the country’s ongoing struggles with pharmaceutical supply chain security and regulatory oversight, continuing a pattern of concerns about foreign ingredient sourcing that has persisted across multiple administrations.